Covered recipient · General Payments record
BARRY A HENDIN
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$287,949.77
386 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $135,747.00 | 42 |
| Consulting Fee | $95,795.50 | 19 |
| Honoraria | $26,175.00 | 12 |
| Travel and Lodging | $20,030.51 | 35 |
| Food and Beverage | $10,124.11 | 277 |
| Education | $77.65 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
Page 4 of 8; records 151–200 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BARRY A HENDIN
NPI 1447239231 · CMS profile ID 201693
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
PHOENIX, AZ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 8; records 151–200 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447239231?year=2023&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447239231?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447239231?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 386 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1447239231?year=2023&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
386 matching records · $287,949.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 386.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| EMD Serono, Inc. | $2,088.00 | 09/01/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032403663 | CMS |
| Novartis Pharmaceuticals Corporation | $9.14 | 08/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991992475 | CMS |
| Alexion Pharmaceuticals, Inc. | $346.80 | 08/30/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016992601 | CMS |
| Alexion Pharmaceuticals, Inc. | $294.32 | 08/30/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016996269 | CMS |
| Alexion Pharmaceuticals, Inc. | $70.17 | 08/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017050163 | CMS |
| EMD Serono, Inc. | $2,088.00 | 08/30/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032406833 | CMS |
| EMD Serono, Inc. | $4,593.00 | 08/30/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032414229 | CMS |
| Biogen, Inc. | $11.60 | 08/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012235179 | CMS |
| Genentech USA, Inc. | $24.56 | 08/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040309405 | CMS |
| Horizon Therapeutics plc | $56.25 | 08/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987018465 | CMS |
| Biogen, Inc. | $38.00 | 08/25/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012223683 | CMS |
| Biogen, Inc. | $3,678.00 | 08/25/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012285645 | CMS |
| Genentech USA, Inc. | $22.75 | 08/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040309416 | CMS |
| Alexion Pharmaceuticals, Inc. | $31.87 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017082497 | CMS |
| Corium, LLC | $10.99 | 08/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 978486097 | CMS |
| TG Therapeutics, Inc. | $24.90 | 08/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051491265 | CMS |
| EMD Serono, Inc. | $5,040.00 | 08/18/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1052754671 | CMS |
| Novartis Pharmaceuticals Corporation | $21.81 | 08/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991992471 | CMS |
| TG Therapeutics, Inc. | $15.29 | 08/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051491419 | CMS |
| EMD Serono, Inc. | $9,603.00 | 08/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032403077 | CMS |
| EMD Serono, Inc. | $6,263.00 | 08/16/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032403549 | CMS |
| Genentech USA, Inc. | $4.50 | 08/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040309429 | CMS |
| Mallinckrodt Hospital Products Inc. | $22.83 | 08/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042839431 | CMS |
| ARGENX US, INC. | $105.90 | 08/15/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060404989 | CMS |
| BANNER LIFE SCIENCES, LLC | $24.90 | 08/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021113225 | CMS |
| Celgene Corporation | $8.99 | 08/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015660543 | CMS |
| Horizon Therapeutics plc | $83.37 | 08/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987018461 | CMS |
| Horizon Therapeutics plc | $52.75 | 08/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987018457 | CMS |
| ARGENX US, INC. | $27.66 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060404925 | CMS |
| BANNER LIFE SCIENCES, LLC | $1.46 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021113145 | CMS |
| BANNER LIFE SCIENCES, LLC | $10.99 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021113147 | CMS |
| Biogen, Inc. | $22.77 | 08/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012173405 | CMS |
| EMD Serono, Inc. | $23.23 | 08/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032318741 | CMS |
| TG Therapeutics, Inc. | $9.16 | 08/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051491221 | CMS |
| TG Therapeutics, Inc. | $101.99 | 08/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051491251 | CMS |
| Acorda Therapeutics, Inc | $2.26 | 07/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1005342177 | CMS |
| Acorda Therapeutics, Inc | $11.07 | 07/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1005342179 | CMS |
| EMD Serono, Inc. | $32.04 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032306121 | CMS |
| Horizon Therapeutics plc | $4,400.00 | 07/26/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987018453 | CMS |
| Novartis Pharmaceuticals Corporation | $11.24 | 07/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 991992467 | CMS |
| Celgene Corporation | $17.81 | 07/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015660527 | CMS |
| Biogen, Inc. | $9.38 | 07/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012207581 | CMS |
| Horizon Therapeutics plc | $107.33 | 07/20/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987018451 | CMS |
| Amneal Pharmaceuticals LLC | $16.48 | 07/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1053499061 | CMS |
| BANNER LIFE SCIENCES, LLC | $7.60 | 07/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021112719 | CMS |
| BANNER LIFE SCIENCES, LLC | $11.04 | 07/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1021112723 | CMS |
| Biogen, Inc. | $133.00 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012139115 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,618.00 | 07/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015660523 | CMS |
| EMD Serono, Inc. | $2,088.00 | 07/18/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1032409919 | CMS |
| TG Therapeutics, Inc. | $31.39 | 07/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1051491397 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,433.92 | 4 |
| PY2025 | Principal investigator | $465,283.11 | 18 |
| PY2024 | Recipient | $1,997.07 | 3 |
| PY2024 | Principal investigator | $119,785.94 | 4 |
| PY2023 | Recipient | $21,685.00 | 1 |
| PY2023 | Principal investigator | $572,937.80 | 16 |
| PY2022 | Recipient | $10,861.00 | 5 |
| PY2022 | Principal investigator | $381,064.86 | 11 |
| PY2021 | Recipient | $2,451.00 | 1 |
| PY2021 | Principal investigator | $334,583.62 | 39 |
| PY2020 | Recipient | $7,508.96 | 3 |
| PY2020 | Principal investigator | $47,007.77 | 20 |
| PY2019 | Principal investigator | $168,349.27 | 47 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
22 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Novartis Pharmaceuticals Corporation | $783.52 | 11/07/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291733 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,395.16 | 10/08/2025 | Non-covered Recipient Entity CENTER FOR NEUROLOGY AND SPINE | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190311285 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $878.52 | 10/06/2025 | Non-covered Recipient Entity PERSEVERANCE RESEARCH CENTER LLC | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190312943 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $270.00 | 10/01/2025 | Non-covered Recipient Entity CENTER FOR NEUROLOGY AND SPINE | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis | No dispute reported | 06/30/2026 | 1190311289 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $453.00 | 10/01/2025 | Non-covered Recipient Entity CENTER FOR NEUROLOGY AND SPINE | A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis | No dispute reported | 06/30/2026 | 1190311291 |
| Principal investigator 1 | Celgene Corporation | $4,500.00 | 09/26/2025 | Non-covered Recipient Entity Perseverance Research Center | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1222306353 |
| Recipient | Novartis Pharma AG | $18.62 | 09/25/2025 | Covered Recipient Physician | COMB157Q12301 | No dispute reported | 06/30/2026 | 1248109099 |
| Principal investigator 1 | EMD Serono, Inc. | $345.00 | 09/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117969 |
| Principal investigator 1 | EMD Serono, Inc. | $1,700.00 | 09/22/2025 | Non-covered Recipient Entity Perseverance Research Center LLC | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118457 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $423.00 | 09/01/2025 | Non-covered Recipient Entity PERSEVERANCE RESEARCH CENTER LLC | A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R | No dispute reported | 06/30/2026 | 1190312945 |
| Recipient | Novartis Pharmaceuticals Corporation | $1,356.78 | 06/03/2025 | Covered Recipient Physician | Research Publication/Writing Support | No dispute reported | 06/30/2026 | 1190292383 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,068.11 | 05/27/2025 | Non-covered Recipient Entity Perseverance Research Center | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1235994716 |
| Principal investigator 1 | EMD Serono, Inc. | $1,345.00 | 05/22/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117965 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,327.80 | 04/30/2025 | Non-covered Recipient Entity Perseverance Research Center | A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. | No dispute reported | 06/30/2026 | 1235994718 |
| Principal investigator 1 | EMD Serono, Inc. | $580.00 | 04/09/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117977 |
| Principal investigator 1 | EMD Serono, Inc. | $1,280.00 | 04/09/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117980 |
| Principal investigator 1 | EMD Serono, Inc. | $410.00 | 03/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117973 |
| Principal investigator 1 | EMD Serono, Inc. | $440.00 | 03/24/2025 | Non-covered Recipient Entity Advarra, Inc. | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240117984 |
| Recipient | Novartis Pharma AG | $2,275.00 | 03/18/2025 | Covered Recipient Physician | COMB157Q12301 | No dispute reported | 06/30/2026 | 1248109101 |
| Principal investigator 1 | EMD Serono, Inc. | $23,601.00 | 03/06/2025 | Non-covered Recipient Entity Perseverance Research Center LLC | Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) | No dispute reported | 06/30/2026 | 1240118459 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $57,031.73 | 01/31/2025 | Non-covered Recipient Entity PHOENIX NEUROLOGICAL ASSOCIATES LTD | A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light | No dispute reported | 06/30/2026 | 1190303209 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $367,234.79 | 01/08/2025 | Non-covered Recipient Entity CENTER FOR NEUROLOGY AND SPINE | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib | No dispute reported | 06/30/2026 | 1190311287 |